Clinical Trials Directory

Trials / Completed

CompletedNCT03860870

Response to Clenbuterol in Humans

Detectability of Clenbuterol and Physiological Response in Human Skeletal Muscle

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
University of Copenhagen · Academic / Other
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Due to the long half-life (\~36 hr) of clenbuterol, detection methods such as dried blood spots (DBS) are a potentially suitable method to easily and non-invasively detect doping misuse of this compound for several days after ingestion. If, and how long, the compound can be detected by DBS has not yet been investigated but is of interest due to its potential in doping-control. The aim is to evaluate whether abuse of clenbuterol can be detected at relevant concentration levels in samples obtained using DBS and to assess the physiological response to clenbuterol in skeletal muscle..

Conditions

Interventions

TypeNameDescription
DRUGClenbuterol Oral ProductSubjects ingest 4x20 microgram clenbuterol tablets
DRUGPlaceboSubjects ingest placebo tablets

Timeline

Start date
2019-03-11
Primary completion
2022-12-21
Completion
2022-12-21
First posted
2019-03-04
Last updated
2024-08-09

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03860870. Inclusion in this directory is not an endorsement.

Response to Clenbuterol in Humans (NCT03860870) · Clinical Trials Directory